The global swine respiratory diseases treatment market size is calculated at USD 2,244 million in 2024 and is predicted to reach around USD 4,173 million by 2034, expanding at a CAGR of 6.4% from 2024 to 2034.
The respiratory diseases in pigs are caused by numerous pathogens, one of the most common pathogens responsible is Enzootic pneumonia (EP). When EP is further combined with viral agents such as Porcine Respiratory and Reproductive Syndrome Virus (PRRSV), Porcine Cirocvirus Type 2 (PCV2) and/or Swine Influenza Virus (SIV) it becomes part of Porcine Respiratory Disease Complex (PRDC), which causes serious problems within pig production. Enzootic pneumonia is a contagious respiratory tract infection caused by the pulmonary bacterial pathogen Mycoplasma hyopneumoniae. The demand for swine respiratory disease treatment market is rising due to the increasing number of foodborne and zoonotic diseases.
The swine respiratory disease treatment market is expected to grow in the foreseeable future with advanced research and development spending and revenue owning to external partnerships and strategic alliances among industries and academia. Additionally, the market has an opportunistic perspective towards government initiatives in emerging countries. The government investment will significantly help in healthcare infrastructure modernization. The high-economic countries such as the UK and the USA are anticipated to focus on innovations to prevent zoonotic diseases combined with biotechnology advancements.
Published by Rohan Patil
